Results 11 to 20 of about 804,384 (336)

Outcomes After Combined Modality Therapy For EGFR-mutant and Wild-Type Locally Advanced NSCLC [PDF]

open access: yesThe Oncologist, 2011
Background Epidermal growth factor receptor (EGFR) mutations identify a unique biological subtype of non-small cell lung cancer (NSCLC). Treatment outcomes for EGFR-mutant locally advanced NSCLC patients have not been well-described.
R. Mak   +9 more
semanticscholar   +2 more sources

Comparing Oncologic Outcomes and Toxicity for Combined Modality Therapy vs. Carbon-Ion Radiotherapy for Previously Irradiated Locally Recurrent Rectal Cancer. [PDF]

open access: yesCancers (Basel), 2023
No standard treatment paradigm exists for previously irradiated locally recurrent rectal cancer (PILRRC). Carbon-ion radiotherapy (CIRT) may improve oncologic outcomes and reduce toxicity compared with combined modality therapy (CMT).
Jeans EB   +17 more
europepmc   +2 more sources

National Patterns of Care and Outcomes after Combined Modality Therapy for Stage IIIA Non-small Cell Lung Cancer [PDF]

open access: yesJournal of Thoracic Oncology, 2014
Introduction: The role of surgery in addition to chemotherapy and radiation for stage IIIA non–small-cell lung cancer (NSCLC) remains controversial.
Aalok P Patel   +12 more
semanticscholar   +2 more sources

Management of Locally Advanced Esophageal Cancer

open access: yesJournal of Nepal Medical Association, 2021
Esophageal cancer is diagnosed usually at a locally advanced stage. Surgery alone has less optimal results and a multimodality approach has been established as the standard of care for cII-III stages of esophageal cancer.
Binay Thakur   +2 more
doaj   +3 more sources

Improved Management of the Advanced Nonseminomatous Testis Cancer

open access: yesRevista Brasileira de Cancerologia, 2023
With the VAB-6 program about 90% (54/59) of patients with stage III and bulky stage II disease achieved complete remission and eighty percent remain free of disease.
Davor Vugrin
doaj   +1 more source

Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia

open access: yesArchives of Endocrinology and Metabolism, 2021
Objectives: To evaluate the effectiveness of adding dapagliflozin as an intensification strategy for the treatment of patients with uncontrolled type 2 diabetes mellitus (T2DM). Materials and methods: A historical cohort study was conducted in 123 adult
Vanessa Bedoya Joaqui   +7 more
doaj   +1 more source

Maintaining treatment of locally advanced breast cancer [PDF]

open access: yesArchive of Oncology, 2003
Locally advanced breast cancer is a specific clinic entity, comprising various degrees of breast cancer local and regional extension. This term is applied to nonmetastatic large primary tumors (including inflammatory breast carcinoma), with or without ...
Muzikravić Ljubomir B.   +3 more
doaj   +1 more source

Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2017
: In this review, the most relevant and current epidemiological data, the main clinical, laboratory and therapeutical aspects of leprosy are presented. Detailed discussion of the main drugs used for leprosy treatment, their most relevant adverse effects,
Rossilene Conceição da Silva Cruz   +4 more
doaj   +1 more source

Conservative treatment of lymphedema: the state of the art

open access: yesJornal Vascular Brasileiro, 2021
This article aims to discuss the possibilities of conservative and non-pharmacological treatments for lymphedema. A non-systematic review of the literature was carried out, including studies involving human subjects with different types of lymphedema ...
Anke Bergmann   +2 more
doaj   +1 more source

Combined modality therapy of Ewing's sarcoma [PDF]

open access: yesCancer, 1975
Since 1964, 66 consecutive patients with Ewing's sarcoma have been treated at the National Cancer Institute with local irradiation of the primary site combined with adjuvant regimens of progressively more intensive systemic chemotherapy. Actuarial survival rates for the total series show a 56% 2-year and 35% 5-year survival.
T C, Pomeroy, R E, Johnson
openaire   +2 more sources

Home - About - Disclaimer - Privacy